Health Care & Life Sciences » Pharmaceuticals | Bio-Path Holdings Inc.

Bio-Path Holdings Inc. | Key People and Executives

Peter H. Nielsen
Chairman, President, CEO, CFO & Treasurer
Douglas P. Morris
Secretary & Non-Independent Director
Paul D. Aubert
Independent Director
Mark P. Colonnese
Independent Director
Heath W. Cleaver
Independent Director
Peter H. Nielsen
Chairman, President, CEO, CFO & Treasurer
Anthony Price
Director-Finance & Accounting
Ana Tari Ashizawa
Vice President-Research & Development
William F. Hahne
Vice President-Clinical Research
Douglas P. Morris
Secretary & Non-Independent Director
Paul D. Aubert
Independent Director
Mark P. Colonnese
Independent Director
Heath W. Cleaver
Independent Director

About Bio-Path Holdings

View Profile
Address
4710 Bellaire Boulevard
Bellaire Texas 77401
United States
Employees -
Website http://www.biopathholdings.com
Updated 07/08/2019
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company utilizing a novel technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Its platform DNAbilize, uses P-ethoxy, which is a deoxyribonucleic acid backbone modification that is intended to protect the DNA from destruction by the body's enzymes when circulating in vivo, incorporated inside of a neutral charged lipid bilayer. The company was founded by Peter Nielsen, Douglas P.